Sickle Cell Disease Market to Witness Growth by 2032, Estimates DelveInsight | Key Companies – Glycomimetics, Global Blood Therapeutics, CSL Behring, Sanofi

Sickle Cell Disease Market to Witness Growth by 2032, Estimates DelveInsight | Key Companies - Glycomimetics, Global Blood Therapeutics, CSL Behring, Sanofi
DelveInsight’s “Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology, as well as the Sickle Cell Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Sickle Cell Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sickle Cell Disease pipeline products will significantly revolutionize the Sickle Cell Disease market dynamics.  

 

Sickle Cell Disease Overview

Sickle cell disease (SCD) is a group of inherited red blood cell disorders caused by a structural abnormality of hemoglobin called sickle hemoglobin (HbS) which encodes hemoglobin subunit β. HbS is inherited in an autosomal recessive way and can occur due to homozygosity for HbS (HbSS). HbS is functional and soluble when oxygenated, but upon deoxygenation, it polymerizes, leading to the generation of deformed red blood cells known as sickled cells and dense erythrocytes.

Some of the key facts of the Sickle Cell Disease Market Report: 

  • The Sickle Cell Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • According to a study published by Sedrak and Kondamudi, sickle cell anemia is the most common monogenic disorder 
  • The Prevalence of Sickle Cell Disease is high among the people of Sub-Saharan Africa, South Asia, the Middle East, and the Mediterranean 
  • Key Sickle Cell Disease Companies: Glycomimetics, Global Blood Therapeutics, CSL Behring, Sanofi, and others 
  • Key Sickle Cell Disease Therapies: GMI-1687, Inclacumab, CSL889, BIVV003, and others 
  • The Sickle Cell Disease epidemiology based on gender analyzed that Sickle Cell Disease affects males and females equally

 

Get a Free sample for the Sickle Cell Disease Market Report 

 

Key benefits of the Sickle Cell Disease Market report:

  1. The Sickle Cell Disease market report covers a descriptive overview and comprehensive insight of the Sickle Cell Disease Epidemiology and Sickle Cell Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Sickle Cell Disease market report provides insights on the current and emerging therapies.
  3. Sickle Cell Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Sickle Cell Disease market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Sickle Cell Disease market.
  5.  

Discover more about therapies set to grab major Sickle Cell Disease market share @ Sickle Cell Disease market forecast 

 

Sickle Cell Disease Epidemiology Segmentation:

The Sickle Cell Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Sickle Cell Disease
  • Prevalent Cases of Sickle Cell Disease by severity
  • Gender-specific Prevalence of Sickle Cell Disease
  • Diagnosed Cases of Episodic and Chronic Sickle Cell Disease 

 

Sickle Cell Disease Market  

The dynamics of the Sickle Cell Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Inclacumab, CSL889, and others during the forecasted period 2019-2032. 

“Vertex Pharma’s CTX001, an investigational ex vivo CRISPR gene-edited therapy, is currently under Phase II/III stage of development in collaboration with CRISPR Therapeutics.” 

 

Download the report to understand which factors are driving Sickle Cell Disease epidemiology trends @ Sickle Cell Disease Epidemiological Insights

 

Sickle Cell Disease Therapies and Key Companies

  • GMI-1687: Glycomimetics
  • Inclacumab: Global Blood Therapeutics
  • CSL889: CSL Behring
  • BIVV003: Sanofi

 

Scope of the Sickle Cell Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Sickle Cell Disease Companies:  Glycomimetics,  Global Blood Therapeutics, CSL Behring, Sanofi, and others
  • Key Sickle Cell Disease Therapies:  GMI-1687, Inclacumab, CSL889, BIVV003, and others
  • Sickle Cell Disease Therapeutic Assessment:  Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies
  • Sickle Cell Disease Market Dynamics:  Sickle Cell Disease market drivers and barriers 
  • Competitive Intelligence Analysis:  SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Sickle Cell Disease  Market Access and Reimbursement

 

Table of Contents 

1. Sickle Cell Disease Market Report Introduction

2. Executive Summary for Sickle Cell Disease

3. SWOT analysis of Sickle Cell Disease

4. Sickle Cell Disease Patient Share (%) Overview at a Glance

5. Sickle Cell Disease Market Overview at a Glance

6. Sickle Cell Disease Disease Background and Overview

7. Sickle Cell Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Sickle Cell Disease 

9. Sickle Cell Disease Current Treatment and Medical Practices

10. Sickle Cell Disease Unmet Needs

11. Sickle Cell Disease Emerging Therapies

12. Sickle Cell Disease Market Outlook

13. Country-Wise Sickle Cell Disease Market Analysis (2019–2032)

14. Sickle Cell Disease Market Access and Reimbursement of Therapies

15. Sickle Cell Disease Market drivers

16. Sickle Cell Disease Market barriers

17.  Sickle Cell Disease Appendix

18. Sickle Cell Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Sickle Cell Disease treatment, visit @ Sickle Cell Disease Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/